TITLE

Risk classification for drug use during pregnancy

AUTHOR(S)
Jafarzadeh, F.; Peymani, P.; Bagheri Lankarani, K.
PUB. DATE
June 2014
SOURCE
Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p79
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Introduction: In many countries, risk classification systems have been set up to summarize the sparse data of drug safety during pregnancy. But, these have resulted in ambiguous statements that are often difficult to compare, interpret and use with accuracy when counseling patients on drug use in pregnancy. The objective of this study was to compare and analyses the correlation and consistency between and the criteria for risk classification for medications used during pregnancy. Materials and Methods: Risk classification systems from the US Food and Drug Administration (FDA), the Australian Drug Evaluation Committee (ADEC) and the Swedish Catalogue of Approved Drugs (FASS), were evaluated, reviewed and compared on basis of the risk factor typology to which they had been assigned. Also, evidence on teratogenicity and adverse effects during pregnancy was retrieved using Medline. Results: Risk factor category allocation for 645 drugs classified by the FDA, 446 classified by ADEC and 527 classified by FASS was compared. Only 61 (26%) of the 236 drugs common to all 3 systems were placed in the same risk factor category. Analysis of studies on the safety of common drugs during pregnancy of drugs classified as X by the FDA showed that the variability in category allocation was not only attributable to the different definitions for the categories. Conclusion: Differences in category allocation for the same drug can be a source of great confusion among users of the classification systems as well as for those who require information regarding risk for drug use during pregnancy.
ACCESSION #
96841676

 

Related Articles

  • Developmental exposure to fenproporex: reproductive and morphological evaluation. Moreira, C. Q.; Faria, M. J. S. S.; Baroneza, J. E.; Oliveira, R. J.; Moreira, E. G. // Human & Experimental Toxicology;Aug2005, Vol. 24 Issue 8, p397 

    This study was designed to evaluate the maternal toxicity and teratogenicity of fenproporex, one of the most widely-used anorectic drugs in many countries, including Brazil. Three periods of exposure were evaluated: (a) 30 days before mating; (b) from gestational day (GD) 0 to 14; and (c) 30...

  • Deprenyl Enhances the Teratogenicity of Hydroxyurea in Organogenesis Stage Mouse Embryos. Schlisser, Ava E.; Hales, Barbara F. // Toxicological Sciences;Aug2013, Vol. 134 Issue 2, p391 

    Hydroxyurea, an antineoplastic drug, is a model teratogen. The administration of hydroxyurea to CD1 mice on gestation day 9 induces oxidative stress, increasing the formation of 4-hydroxy-2-nonenal adducts to redox-sensitive proteins such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in...

  • Gebelikte Psikotrop Ä°laç Kullanımı: Bir Güncelleme. Çetin, Mesut // Klinik Psikofarmakoloji Bulteni;Jun2011, Vol. 21 Issue 2, p161 

    Pregnancy is a turbulent period, during which hormonal and psychosocial lifestyle changes occur. Hence depression, anxiety disorders, or obsessive-compulsive disorders can be triggered and chronic psychiatric disorders can be exacerbated, particularly, due to limitations on the use of...

  • Teratogenicity with Olanzapine. Prakash, Sathya; Kumar Chadda, Rakesh // Indian Journal of Psychological Medicine;Jan-Mar2014, Vol. 36 Issue 1, p91 

    Olanzapine, a 2nd generation antipsychotic, is in use in the clinical practice for nearly a decade and a half now. It is classified as a category C drug with very few reports of its toxic effects on the fetus. In general, the risk benefit analysis warrants its use in pregnancy. We report a case...

  • Which Drug for the Pregnant Woman with Epilepsy? Tomson, Torbj�rn // New England Journal of Medicine;4/16/2009, Vol. 360 Issue 16, p1667 

    The author discusses the challenges facing physicians in prescribing drugs that are effective in controlling seizures in women with epilepsy during pregnancy. It is argued that research on the teratogenicity of antiepileptic drugs has focused on anatomical birth defects, while little attention...

  • New drugs for the treatment of epilepsy: a practical approach. Beyenburg, S.; Bauer, J.; Reuber, M. // Postgraduate Medical Journal;Oct2004, Vol. 80 Issue 948, p581 

    The availability of new antiepileptic drugs has broadened the spectrum of medical treatment options in epilepsy. The new agents, together with established drugs, offer substantial choice for doctors treating patients with focal or generalised epilepsy. The newer antiepileptic drugs are not...

  • Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes: The General Practice Research Database (GPRD) as an Alternative to Pregnancy Registries. Charlton, Rachel A.; Cunnington, Marianne C.; de Vries, Corinne S.; Weil, John G. // Drug Safety;2008, Vol. 31 Issue 1, p39 

    Pregnancy registries are the most commonly used data resource for the post-marketing surveillance of drug teratogenicity. However, the limited sample size and potential selection bias in these registries has led us to investigate the potential of the UK General Practice Research Database (GPRD)...

  • Teratogenic Effects of Diazepam Intake During Pregnancy Leading to Cleft Lip and Palatal Anomalies. Takzare, Nasrin; Hosseini, Mir-Jamal; Takzare, Alireza; Bakhtiarian, Azam; Yarmohammadi, Kamran // Journal of Medical Sciences;2007, Vol. 7 Issue 7, p1177 

    In this research, it has studied the teratogenicity of Diazepam intake during pregnancy and its effects on cleft lip and palatal development. About 30 virgin rats of known age and weight were used. After pregnancy, they were divided in three groups: The first groups were control group which were...

  • EVALUATION OF THE TERATOGENICITY OF AQUEOUS EXTRACT OF Labisia pumila var. alata IN RATS. Wan Ezumi Mohd Fuad; Siti Amrah Sulaiman; Mohamad Nazrul Islam; Mohd Suhaimi Abdul Wahab; Syed Mohsin Sahil Jamalullail // Malaysian Journal of Medical Sciences;Jul2005, Vol. 12 Issue 2, p13 

    A dose range study to assess the teratogenic potential of aqueous extract of Labisia pumila var. alata (Kacip Fatimah) was conducted in rodents. The extract at doses of 0 (control), 2, 20, 200, 400, 1000 mg/kg/day were respectively administered by gavaging to 6 groups of pregnant Sprague Dawley...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics